ReviewChinese medicine2025
An exhaustive examination of the research progress in identifying potential JAK inhibitors from natural products: a comprehensive overview.
Review in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Decoding the PI3K/Akt/mTOR-JAK/STAT signaling axis in multiple sclerosis: mechanistic crosstalk and therapeutic opportunities.Immunologic research · 2026Review
- Tiaozhi Tongmai Formula attenuates atherosclerosis by modulating the JAK1/STAT3 pathway to inhibit phenotypic transformation of vascular smooth muscle cells.Cardiovascular diagnosis and therapy · 2026Article
- Exploring the anti-inflammatory effects of genistein in an in vitro lipopolysaccharide-induced macrophage model.Scientific reports · 2026Article
- Rus-GXF, a ruscogenin glycoside, binds to the ADP-binding domain of JAK1 to prevent inflammation and barrier damage in acute lung injury.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The JAK-STAT signaling pathway serves as a central regulator of diverse cellular processes encompassing proliferation, apoptosis, inflammation, and differentiation. Specifically, extracellular ligands such as interleukins, and colony-stimulating factors induce JAKs phosphorylation, subsequently triggering dimerization and nuclear translocation of STATs protein. In this way, the JAK-STAT pathway modulates target gene expression. Dysregulation of the JAK-STAT pathways has been implicated in the pathogenesis of multiple diseases, including inflammatory diseases, autoimmune diseases, malignant tumors. Therefore, JAK inhibitors have been considered promising therapeutic candidates with substantial clinical potential. While previous reviews have primarily focused on natural products targeting JAK-STAT signaling pathways for the specific disease application, this paper comprehensively collected 88 natural products demonstrating JAKs inhibitory activity across multiple pathological conditions. We mainly referenced nearly 20 years of literature from 2005 to 2025, comprising 294 different types of publications including review articles and research papers. Through systematic analysis of the compounds, we further classified these phytochemicals according to their structural characteristics (flavonoids, alkaloids, terpenoids) and molecular targets within the signaling cascades. This study provides novel insights into the pathophysiological relationships between diseases and JAK kinases, while offering valuable guidance for developing next-generation JAK inhibitors with improved therapeutic profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.